Drug Trial Radar · NCT04574869
A Study of RLS-0071 in Patients With Acute Lung Injury Due to COVID-19 Pneumonia in Early Respiratory Failure
Last checked: Nov 19, 2026Latest source record: Feb 4, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Jan 2021
Primary completion
Sep 2022
Study completion Dec 2022
Sponsor
- Lead sponsor
- ReAlta Life Sciences, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 5, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 69 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this study will test the safety, tolerability, and efficacy of RLS-0071 for approximately 28 days in comparison to a placebo control in patients with acute lung injury due to COVID-19 pneumonia in early respiratory failure. Patients will be randomized and double-blinded for two parts, a single-ascending dose (SAD) part and a multiple-ascending dose (MAD) part. The name of the study drug involved in this study is: RLS-0071.
Conditions
- Acute Lung Injury
- ALI
- COVID-19
Interventions
RLS-0071 10 mg/kgDrug
Single dose IV infusion of 10 mg/kg RLS-0071
RLS-0071 40 mg/kgDrug
Single dose IV infusion of 40 mg/kg RLS-0071
PlaceboDrug
The placebo control will be commercial sterile saline (0.9% Sodium Chloride Injection, United States Pharmacopoeia \[USP\]).
RLS-0071 10 mg/kgDrug
Multiple dose IV infusion of 10 mg/kg RLS-0071 administered every 8 hours for approximately 3 days (9 consecutive doses)
RLS-0071 40 mg/kgDrug
Multiple dose IV infusion of 40 mg/kg RLS-0071 administered every 8 hours for approximately 3 days (9 consecutive doses)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency and severity of Adverse Events, including Serious Adverse Events, by treatment group and dose level, including the frequency of premature discontinuation of study intervention due to Adverse Events.Time frame: Through study completion at Day 28 following last dose.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Henry Ford Health Systems
Detroit, Michigan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.